BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best mid-cap growth stocks to buy right now. On January 14, Bank of America lowered its price target on Travere Therapeutics to $43 from $47, ...

Swiss HBM Healthcare nine-month profit hits CHF 286 mln as NAV jumps 18%

Investing.com -- HBM Healthcare Investments (SIX: HBMN) on Friday reported a quarterly profit of CHF 191 million in the third quarter, bringing nine-month earnings to CHF 286 million despite currency ...